REGENXBIO Inc. (RGNX)
Automate Your Wheel Strategy on RGNX
With Tiblio's Option Bot, you can configure your own wheel strategy including RGNX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RGNX
- Rev/Share 3.0512
- Book/Share 5.3385
- PB 1.6053
- Debt/Equity 0.2912
- CurrentRatio 2.9348
- ROIC -0.4013
- MktCap 429873771.0
- FreeCF/Share -1.6928
- PFCF -4.9443
- PE -2.7914
- Debt/Assets 0.1626
- DivYield 0
- ROE -0.5329
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RGNX | Goldman | Buy | Neutral | $38 | $14 | Feb. 11, 2025 |
| Resumed | RGNX | Raymond James | -- | Outperform | -- | $27 | Feb. 7, 2025 |
| Resumed | RGNX | Raymond James | -- | Outperform | -- | $18 | Oct. 10, 2024 |
News
Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer
Published: June 05, 2025 by: Benzinga
Sentiment: Positive
RegenXBio Inc. RGNX revealed new interim data on Thursday from the Phase 1/2 AFFINITY DUCHENNE trial.
Read More
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
Published: June 05, 2025 by: PRNewsWire
Sentiment: Neutral
RGX-202 demonstrating consistent evidence of positively changing disease trajectory for Duchenne All dose level 2 participants exceeded external natural history controls on all functional measures Biomarker data demonstrate consistent, robust microdystrophin expression and transduction levels across all treated ages One new participant aged 2 years at dosing had expression level at 118.6% compared to control Favorable safety profile continues with no serious adverse events or adverse events of special interest observed Webcast to be held at 8:00 a.m. today ROCKVILLE, Md.
Read More
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial ROCKVILLE, Md.
Read More
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
ROCKVILLE, Md. , May 8, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New Orleans, May 13 through 17, 2025.
Read More
REGENXBIO to Participate in Upcoming Investor Conferences
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
ROCKVILLE, Md. , May 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: BofA Securities Health Care Conference 2025 Presentation: Tuesday, May 13, 2025 at 5:00 p.m.
Read More
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
5 Reasons To Buy Regenxbio Right Now
Published: March 26, 2025 by: Seeking Alpha
Sentiment: Positive
Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, with potential for the EV to turn negative once upcoming scheduled/milestone payments and royalties come in. RGNX benefits from strategic partnerships, including $110M from Nippon Shinyaku and $200M from AbbVie, plus potential higher royalties from Novartis.
Read More
REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY
Published: March 19, 2025 by: PRNewsWire
Sentiment: Neutral
Positive biomarker data in patient aged 1-3 add to consistent, robust microdystrophin and transduction levels across all treated ages Patient aged 3 years at dosing had expression level at 122.3% compared to control With a differentiated novel construct and proactive short course immune modulation regimen, RGX-202 continues to demonstrate encouraging safety profile with no SAEs or AESIs Phase III portion of AFFINITY DUCHENNE® trial enrolling ambulatory patients aged 1 and above, on track for BLA submission mid-2026 ROCKVILLE, Md. , March 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in …
Read More
Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Published: February 11, 2025 by: Benzinga
Sentiment: Negative
Goldman Sachs downgraded Regenxbio Inc RGNX, citing gene therapy's appeal for wet AMD and diabetic retinopathy is uncertain, as most patients are elderly and newer anti-VEGF treatments offer longer-lasting effects at lower costs.
Read More
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 333% upside potential for Regenxbio (RGNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
About REGENXBIO Inc. (RGNX)
- IPO Date 2015-09-17
- Website https://www.regenxbio.com
- Industry Biotechnology
- CEO Mr. Curran M. Simpson M.S.
- Employees 353